Clinical Trial Update: Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery [EARLY_Phase 1]

View source ↗

Summary

An early-phase clinical trial is evaluating olaparib for newly diagnosed BRCA-mutant ovarian, fallopian tube, or primary peritoneal cancers before surgery; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING